Staff Reports | Community Updates
HonorHealth is launching its artificial heart program following accreditation by DNV in March 2025.
This milestone marks a major advancement in treating advanced heart failure, bringing lifesaving durable mechanical circulatory support to patients across Arizona and the southwest, according to a press release.
Heart failure affects nearly 6.7 million U.S. adults and is expected to rise to 8 million by 2030. In advanced stages, it can mean frequent hospital visits, extreme fatigue, and a much shorter life expectancy, the release states.
With the introduction of cutting-edge Ventricular Assist Device (VAD) technology, HonorHealth is providing a critical option for patients whose hearts can no longer pump enough blood on their own.
“We are excited to increase access for patients with advanced heart failure by offering state-of-the-art ventricular assist device technology which has been shown not only to add years to life but also life to years,” says Geoffrey Jao, MD, medical director of the Advanced Heart Failure and Artificial Heart Program at HonorHealth.
“This means more independence and giving families more quality time together.”
HonorHealth’s program uses the HeartMate 3, a small mechanical pump surgically implanted to help the heart move blood through the body. Today, patients with the HeartMate 3 VAD’s are seeing five-year survival rates approach 60%.
“This is more than a device, it’s a lifeline,” adds Zain Khalpey, MD, surgical director of the Artificial Heart Program. “We’re combining surgical innovation with a personalized, team-based approach. Every patient has a team of experts behind them, all focused on one mission: helping them live longer, fuller lives that reflect their goals and what matters most to them.”
